Human epidermal growth receptor-2 overexpressing early operable primary breast cancers in older (≥70 years) women: biology and clinical outcome in comparison with younger (<70 years) patients
There is dearth of literature reporting the prevalence and biological characteristics as well as the long-term clinical outcome of human epidermal growth factor receptor-2 (HER2) overexpressing tumours in older women. Currently, research involving trastuzumab at large focuses on the younger populati...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2014-04, Vol.25 (4), p.837-842 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 842 |
|---|---|
| container_issue | 4 |
| container_start_page | 837 |
| container_title | Annals of oncology |
| container_volume | 25 |
| creator | Syed, B.M. Green, A.R. Ellis, I.O. Cheung, K.L. |
| description | There is dearth of literature reporting the prevalence and biological characteristics as well as the long-term clinical outcome of human epidermal growth factor receptor-2 (HER2) overexpressing tumours in older women. Currently, research involving trastuzumab at large focuses on the younger population. This study aimed to analyse their biological characteristics and to compare them with their younger counterparts from a single centre with a long-term clinical follow-up.
Over 37 years (1973–2010), 1758 older (≥70 years) women with early operable ( |
| doi_str_mv | 10.1093/annonc/mdu028 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1510713227</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S092375341936510X</els_id><sourcerecordid>1510713227</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-6238695970d1ad1f2be1c7e6ad1acd25e66583f6401963df0473021a138919923</originalsourceid><addsrcrecordid>eNp1kc2O1SAYhonROMfRpVvDxmRc1OGnhWLcmIk6JpO40TWh8PWIaaFCO8deghfihXgrXomc9OisXEHC8718eV6EnlLykhLFL00IMdjL0S2EtffQjjZCVS2p6X20I4rxSja8PkOPcv5KCBGKqYfojNVCSEnFDv26XkYTMEzeQRrNgPcpHuYvOIGFaY6pYjjeQoLvU4KcfdhjMGlYcZwgmW4APCU_mrTiLoHJM7YmWEgZ-4DjUCLxxe8fPyXBaxnLL_AhjhBe4c7HIe5XbILDdvDB2_JzXGZbno-j5ZxM8jkGfPBlmzUuYX8Me30XNZnZQ5jzY_SgN0OGJ6fzHH1-9_bT1XV18_H9h6s3N5WtKZkrwXgrVKMkcdQ42rMOqJUgyt1YxxoQoml5L2pCleCuJ7XkhFFDeauoKiLP0cWWO6X4bYE869FnC8NgAsQla9pQIilnTBa02lCbYs4Jen2ypCnRx9b01preWiv8s1P00o3g_tF_ayrA8xNgclHVp2LZ5zuu5YQKVhdObhwUEbceks62SLLgfCl01i76_6zwB6pXuXA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1510713227</pqid></control><display><type>article</type><title>Human epidermal growth receptor-2 overexpressing early operable primary breast cancers in older (≥70 years) women: biology and clinical outcome in comparison with younger (<70 years) patients</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Syed, B.M. ; Green, A.R. ; Ellis, I.O. ; Cheung, K.L.</creator><creatorcontrib>Syed, B.M. ; Green, A.R. ; Ellis, I.O. ; Cheung, K.L.</creatorcontrib><description>There is dearth of literature reporting the prevalence and biological characteristics as well as the long-term clinical outcome of human epidermal growth factor receptor-2 (HER2) overexpressing tumours in older women. Currently, research involving trastuzumab at large focuses on the younger population. This study aimed to analyse their biological characteristics and to compare them with their younger counterparts from a single centre with a long-term clinical follow-up.
Over 37 years (1973–2010), 1758 older (≥70 years) women with early operable (<5 cm) primary breast cancer were managed in a dedicated clinic and have complete clinical information available. Of these, 813 patients underwent primary surgery and 575 had good quality tumour samples available for tissue microarray analysis using indirect immunohistochemistry. Comparison was made with data from a well-characterised younger (<70 years) series (N = 1711) treated between 1986 and 1998 (before adjuvant trastuzumab became standard) in our institution. Forty five (7.6%) and 140 (8.2%) patients from the older and younger series, respectively, had HER2-positive tumours.
HER2 overexpression was seen in 45 (7.6%) older women and 140 (8.2%) in younger patients (P = 0.56). HER2 overexpressing tumours in older women when compared with that in their younger counterparts were associated with low Ki67 and high bcl2 expression (P < 0.05). Only 26% of the younger patients and none of the older patients received adjuvant chemotherapy, and no patients at the time received trastuzumab. However, there was no significant difference in the outcome of the two age groups (5-year breast cancer-specific survival rate: <70 years = 65% versus >70 years = 70%, P = 0.51).
HER2 overexpressing tumours in older women showed relatively a less aggressive phenotype and did not show any inferior long-term clinical outcome despite not having received chemotherapy when compared with the younger patients. The precise role of different adjuvant systemic therapies in this population needs to be delineated.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdu028</identifier><identifier>PMID: 24667716</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adult ; Age Factors ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols ; Biological and medical sciences ; breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - pathology ; Breast Neoplasms - surgery ; Female ; Gene Expression Regulation, Neoplastic ; Gynecology. Andrology. Obstetrics ; HER2 overexpressing ; Humans ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; older women ; Pharmacology. Drug treatments ; Receptor, ErbB-2 - genetics ; Survival Rate ; Trastuzumab ; Treatment Outcome ; Tumors</subject><ispartof>Annals of oncology, 2014-04, Vol.25 (4), p.837-842</ispartof><rights>2014 European Society for Medical Oncology</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-6238695970d1ad1f2be1c7e6ad1acd25e66583f6401963df0473021a138919923</citedby><cites>FETCH-LOGICAL-c410t-6238695970d1ad1f2be1c7e6ad1acd25e66583f6401963df0473021a138919923</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28301624$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24667716$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Syed, B.M.</creatorcontrib><creatorcontrib>Green, A.R.</creatorcontrib><creatorcontrib>Ellis, I.O.</creatorcontrib><creatorcontrib>Cheung, K.L.</creatorcontrib><title>Human epidermal growth receptor-2 overexpressing early operable primary breast cancers in older (≥70 years) women: biology and clinical outcome in comparison with younger (<70 years) patients</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>There is dearth of literature reporting the prevalence and biological characteristics as well as the long-term clinical outcome of human epidermal growth factor receptor-2 (HER2) overexpressing tumours in older women. Currently, research involving trastuzumab at large focuses on the younger population. This study aimed to analyse their biological characteristics and to compare them with their younger counterparts from a single centre with a long-term clinical follow-up.
Over 37 years (1973–2010), 1758 older (≥70 years) women with early operable (<5 cm) primary breast cancer were managed in a dedicated clinic and have complete clinical information available. Of these, 813 patients underwent primary surgery and 575 had good quality tumour samples available for tissue microarray analysis using indirect immunohistochemistry. Comparison was made with data from a well-characterised younger (<70 years) series (N = 1711) treated between 1986 and 1998 (before adjuvant trastuzumab became standard) in our institution. Forty five (7.6%) and 140 (8.2%) patients from the older and younger series, respectively, had HER2-positive tumours.
HER2 overexpression was seen in 45 (7.6%) older women and 140 (8.2%) in younger patients (P = 0.56). HER2 overexpressing tumours in older women when compared with that in their younger counterparts were associated with low Ki67 and high bcl2 expression (P < 0.05). Only 26% of the younger patients and none of the older patients received adjuvant chemotherapy, and no patients at the time received trastuzumab. However, there was no significant difference in the outcome of the two age groups (5-year breast cancer-specific survival rate: <70 years = 65% versus >70 years = 70%, P = 0.51).
HER2 overexpressing tumours in older women showed relatively a less aggressive phenotype and did not show any inferior long-term clinical outcome despite not having received chemotherapy when compared with the younger patients. The precise role of different adjuvant systemic therapies in this population needs to be delineated.</description><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal, Humanized - administration & dosage</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Biological and medical sciences</subject><subject>breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - surgery</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>HER2 overexpressing</subject><subject>Humans</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>older women</subject><subject>Pharmacology. Drug treatments</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Survival Rate</subject><subject>Trastuzumab</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc2O1SAYhonROMfRpVvDxmRc1OGnhWLcmIk6JpO40TWh8PWIaaFCO8deghfihXgrXomc9OisXEHC8718eV6EnlLykhLFL00IMdjL0S2EtffQjjZCVS2p6X20I4rxSja8PkOPcv5KCBGKqYfojNVCSEnFDv26XkYTMEzeQRrNgPcpHuYvOIGFaY6pYjjeQoLvU4KcfdhjMGlYcZwgmW4APCU_mrTiLoHJM7YmWEgZ-4DjUCLxxe8fPyXBaxnLL_AhjhBe4c7HIe5XbILDdvDB2_JzXGZbno-j5ZxM8jkGfPBlmzUuYX8Me30XNZnZQ5jzY_SgN0OGJ6fzHH1-9_bT1XV18_H9h6s3N5WtKZkrwXgrVKMkcdQ42rMOqJUgyt1YxxoQoml5L2pCleCuJ7XkhFFDeauoKiLP0cWWO6X4bYE869FnC8NgAsQla9pQIilnTBa02lCbYs4Jen2ypCnRx9b01preWiv8s1P00o3g_tF_ayrA8xNgclHVp2LZ5zuu5YQKVhdObhwUEbceks62SLLgfCl01i76_6zwB6pXuXA</recordid><startdate>20140401</startdate><enddate>20140401</enddate><creator>Syed, B.M.</creator><creator>Green, A.R.</creator><creator>Ellis, I.O.</creator><creator>Cheung, K.L.</creator><general>Elsevier Ltd</general><general>Oxford University Press</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140401</creationdate><title>Human epidermal growth receptor-2 overexpressing early operable primary breast cancers in older (≥70 years) women: biology and clinical outcome in comparison with younger (<70 years) patients</title><author>Syed, B.M. ; Green, A.R. ; Ellis, I.O. ; Cheung, K.L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-6238695970d1ad1f2be1c7e6ad1acd25e66583f6401963df0473021a138919923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal, Humanized - administration & dosage</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Biological and medical sciences</topic><topic>breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - surgery</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>HER2 overexpressing</topic><topic>Humans</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>older women</topic><topic>Pharmacology. Drug treatments</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Survival Rate</topic><topic>Trastuzumab</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Syed, B.M.</creatorcontrib><creatorcontrib>Green, A.R.</creatorcontrib><creatorcontrib>Ellis, I.O.</creatorcontrib><creatorcontrib>Cheung, K.L.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Syed, B.M.</au><au>Green, A.R.</au><au>Ellis, I.O.</au><au>Cheung, K.L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Human epidermal growth receptor-2 overexpressing early operable primary breast cancers in older (≥70 years) women: biology and clinical outcome in comparison with younger (<70 years) patients</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2014-04-01</date><risdate>2014</risdate><volume>25</volume><issue>4</issue><spage>837</spage><epage>842</epage><pages>837-842</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>There is dearth of literature reporting the prevalence and biological characteristics as well as the long-term clinical outcome of human epidermal growth factor receptor-2 (HER2) overexpressing tumours in older women. Currently, research involving trastuzumab at large focuses on the younger population. This study aimed to analyse their biological characteristics and to compare them with their younger counterparts from a single centre with a long-term clinical follow-up.
Over 37 years (1973–2010), 1758 older (≥70 years) women with early operable (<5 cm) primary breast cancer were managed in a dedicated clinic and have complete clinical information available. Of these, 813 patients underwent primary surgery and 575 had good quality tumour samples available for tissue microarray analysis using indirect immunohistochemistry. Comparison was made with data from a well-characterised younger (<70 years) series (N = 1711) treated between 1986 and 1998 (before adjuvant trastuzumab became standard) in our institution. Forty five (7.6%) and 140 (8.2%) patients from the older and younger series, respectively, had HER2-positive tumours.
HER2 overexpression was seen in 45 (7.6%) older women and 140 (8.2%) in younger patients (P = 0.56). HER2 overexpressing tumours in older women when compared with that in their younger counterparts were associated with low Ki67 and high bcl2 expression (P < 0.05). Only 26% of the younger patients and none of the older patients received adjuvant chemotherapy, and no patients at the time received trastuzumab. However, there was no significant difference in the outcome of the two age groups (5-year breast cancer-specific survival rate: <70 years = 65% versus >70 years = 70%, P = 0.51).
HER2 overexpressing tumours in older women showed relatively a less aggressive phenotype and did not show any inferior long-term clinical outcome despite not having received chemotherapy when compared with the younger patients. The precise role of different adjuvant systemic therapies in this population needs to be delineated.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>24667716</pmid><doi>10.1093/annonc/mdu028</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2014-04, Vol.25 (4), p.837-842 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1510713227 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Age Factors Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols Biological and medical sciences breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Breast Neoplasms - surgery Female Gene Expression Regulation, Neoplastic Gynecology. Andrology. Obstetrics HER2 overexpressing Humans Mammary gland diseases Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) older women Pharmacology. Drug treatments Receptor, ErbB-2 - genetics Survival Rate Trastuzumab Treatment Outcome Tumors |
| title | Human epidermal growth receptor-2 overexpressing early operable primary breast cancers in older (≥70 years) women: biology and clinical outcome in comparison with younger (<70 years) patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T02%3A19%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Human%20epidermal%20growth%20receptor-2%20overexpressing%20early%20operable%20primary%20breast%20cancers%20in%20older%20(%E2%89%A570%20years)%20women:%20biology%20and%20clinical%20outcome%20in%20comparison%20with%20younger%20(%3C70%20years)%20patients&rft.jtitle=Annals%20of%20oncology&rft.au=Syed,%20B.M.&rft.date=2014-04-01&rft.volume=25&rft.issue=4&rft.spage=837&rft.epage=842&rft.pages=837-842&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdu028&rft_dat=%3Cproquest_cross%3E1510713227%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1510713227&rft_id=info:pmid/24667716&rft_els_id=S092375341936510X&rfr_iscdi=true |